Gina Mauro | Authors

Adding Carboplatin to Neoadjuvant Paclitaxel Improved Outcomes in TNBC

September 18, 2021

Although the addition of carboplatin to neoadjuvant paclitaxel followed by cyclophosphamide helped to improve outcomes for those with treatment-naïve triple-negative breast cancer, the addition of veliparib did not have an impact on pathologic complete response or event-free survival.